CytoMed Therapeutics (GDTC) Stock News
$GDTC · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on CytoMed Therapeutics (GDTC) in the past 30 days. BORSA’s news read on GDTC is bearish at 42/100, unchanged over 24 hours, based on 1 company event over the past 7 days.
The wire on $GDTC
newest first · updated · direct subject stories onlyCytoMed Therapeutics receives Nasdaq minimum bid price deficiency notice
CytoMed Therapeutics (GDTC) disclosed a Nasdaq notice for falling below the $1.00 minimum bid price for 30 consecutive business days. It has until April 5, 2027, to regain compliance by hitting $1.00 for ten consecutive sessions. A second 180-day period may be available. Trading is unaffected for now.
bearish 35 · impact 30